Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

被引：0
|
作者：
Xiaoyang Zhai
Wanhu Li
Ji Li
Wenxiao Jia
Wang Jing
Yaru Tian
Shuhui Xu
Yuying Li
Hui Zhu
Jinming Yu
机构：
[1] Shantou University Medical College,Department of Radiation Oncology, Shandong Cancer Hospital and Institute
[2] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Radiology, Shandong Cancer Hospital and Institute
[3] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[4] Renmin Hospital of Wuhan University,Department of Radiation Oncology
[5] Shandong Cancer Hospital and Institute Affiliated to Shandong University,undefined
[6] Shandong First Medical University,undefined
[7] Shandong Academy of Medical Sciences,undefined
来源：
Radiation Oncology | / 16卷
关键词：
Osimertinib; Cranial radiotherapy; Brain metastases; Leukoencephalopathy; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
    Zhai, Xiaoyang
    Li, Wanhu
    Li, Ji
    Jia, Wenxiao
    Jing, Wang
    Tian, Yaru
    Xu, Shuhui
    Li, Yuying
    Zhu, Hui
    Yu, Jinming
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [2] Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
    Ji, Jingran
    Aredo, Jacqueline, V
    Piper-Vallillo, Andrew
    Huppert, Laura
    Rotow, Julia K.
    Husain, Hatim
    Stewart, Susan
    Cobb, Rosemary
    Wakelee, Heather A.
    Blakely, Collin M.
    Wong, Melisa L.
    Gubens, Matthew A.
    Madani, Mohammad H.
    Digumarthy, Subba R.
    Mccoach, Caroline
    Piotrowska, Zofia
    Neal, Joel W.
    Riess, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):
  • [3] Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : E3 - E4
  • [4] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [5] Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series
    Dohm, A. E.
    Upadhyay, R.
    Tang, J. D.
    Oliver, D. E.
    Perez, B. A.
    Rosenberg, S. A.
    Yu, H. H. M.
    Palmer, J. D.
    Beyer, S.
    Owen, D.
    Ahmed, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E100 - E101
  • [6] Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
    Zhou, Guojin
    Guo, Liuxian
    Xu, Jing
    Tang, Kejing
    Chen, Jie
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [7] Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS plus osimertinib compared to osimertinib alone: the STARLET Collaboration
    Robledo, Kristy P.
    Lefresne, Shilo
    Soon, Yu Yang
    Sahgal, Arjun
    Pinkham, Mark B.
    Nichol, Alan
    Soo, Ross Andrew
    Parmar, Ambika
    Hegi-Johnson, Fiona
    Doherty, Mark
    Solomon, Benjamin J.
    Shultz, David B.
    Tham, Ivan W. K.
    Sacher, Adrian G.
    Tey, Jeremy
    Leong, Cheng Nang
    Koh, Wee Yao
    Huang, Yiqing
    Ang, Yvonne Li En
    Low, Jiali
    Yong, Clement
    Lim, Mei Chin
    Tan, Ai Peng
    Lee, Chee Khoon
    Ho, Cheryl
    BMJ OPEN, 2024, 14 (07):
  • [8] Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Tozuka, Takehiro
    Noro, Rintaro
    Mizutani, Hideaki
    Kurimoto, Futoshi
    Hakozaki, Taiki
    Hisakane, Kakeru
    Naito, Tomoyuki
    Takahashi, Satoshi
    Taniuchi, Namiko
    Yajima, Chika
    Hosomi, Yukio
    Hirose, Takashi
    Minegishi, Yuji
    Okano, Tetsuya
    Kamio, Koichiro
    Yamaguchi, Tomoyoshi
    Seike, Masahiro
    LUNG CANCER, 2024, 191
  • [9] Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
    Pizzutilo, E. G.
    Cerea, G.
    Oresti, S.
    Agostara, A. G.
    Signorelli, D.
    Stabile, S.
    Lauricella, C.
    Brambilla, M.
    Mazzeo, L.
    Giusti, R.
    Montrone, M.
    Russano, M.
    Bennati, C.
    Russo, A.
    Viscardi, G.
    Roca, E.
    Gelibter, A. J.
    Cortinovis, D. L.
    Bianchi, A. Sartore
    Siena, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1009 - S1009
  • [10] Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
    Pizzutilo, E. G.
    Agostara, A. G.
    Oresti, S.
    Signorelli, D.
    Giannetta, L. G.
    Stabile, S.
    Lauricella, C.
    Amatu, A.
    Brambilla, M.
    Lo Russo, G.
    Proto, C.
    Mazzeo, L.
    Beninato, T.
    Siringo, M.
    Giusti, R.
    Filetti, M.
    Genova, C.
    Barletta, G.
    Russano, M.
    Di Fazio, G. R.
    Tosoni, E.
    Metro, G.
    Pilotto, S.
    Carta, A.
    Mazzoni, F.
    Roca, E.
    Gelibter, A. J.
    Gori, S.
    Berardi, R.
    Cerea, G.
    Sartore-Bianchi, A.
    Siena, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S418 - S419
12345